Pembrolizumab vs Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Versus Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE-204): An Interim Analysis of a Multicentre, Randomised, Open-Label, Phase 3 Study
Lancet Oncol 2021 Mar 12;[EPub Ahead of Print], J Kuruvilla, R Ramchandren, A Santoro, E Paszkiewicz-Kozik, R Gasiorowski, NA Johnson, LM Fogliatto, I Goncalves, JSR de Oliveira, V Buccheri, GF Perini, N Goldschmidt, I Kriachok, M Dickinson, M Komarnicki, A McDonald, M Ozcan, N Sekiguchi, Y Zhu, A Nahar, P Marinello, PL ZinzaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.